Prevalence and epidemiological characteristics of patients with diabetic retinopathy in Slovakia: 12-month results from the DIARET SK study


Autoři: Marta Ondrejkova aff001;  Peter Jackuliak aff002;  Emil Martinka aff003;  Marian Mokan aff004;  James Foley aff005;  Jana Fabkova aff006;  Karol Gecik aff006;  Iveta Tvrda aff006;  Miroslav Helbich aff007;  Monika Gajdosova aff001
Působiště autorů: Specialized Hospital in Ophthalmology, Zvolen, Slovakia aff001;  5 Clinic of Internal Medicine, Faculty of Medicine of the Comenius University Bratislava and University Hospital Bratislava, Workplace Hospital, Ruzinov, Slovakia aff002;  National Institute of Endocrinology and Diabetology, Lubochňa, Slovakia aff003;  1 Clinic of Internal Medicine, Jessenius Faculty of Medicine in Martin of the Comenius University in Bratislava, Slovakia aff004;  Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America aff005;  Novartis Slovakia s.r.o., Bratislava, Slovakia aff006;  Caldera s.r.o. Banska Stiavnica, Banska Stiavnica, Slovakia aff007
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223788

Souhrn

Purpose

To evaluate the prevalence and epidemiological characteristics of diabetic retinopathy (DR) in Slovakian patients with Type 1 and 2 diabetes mellitus (DM) in the DIARET SK study.

Patients and methods

An epidemiological multi-center survey that included 4,078 adult patients (aged ≥18 years) from 51 diabetologists and 47 ophthalmologists. Data were collected from February to December 2015.

Results

The final data set consisted of 4,014 patients; 3,700 were enrolled (Type 2 DM = 3,405, Type 1 DM = 295) using a quasi-random approach; 16 (Type 2 DM = 15, Type 1 DM = 1) patients in the pre-specified group had DM duration of <5 years with a history of DR while 298 patients (Type 2 DM = 204, Type 1 DM = 94) had DM duration of ≥ 20 years. The mean (standard deviation [SD]) age of patients at diagnosis for Types 2 and 1 DM was 53.4 (9.5) and 27.6 (12.9) years, respectively. The mean (SD) glycated hemoglobin (HbA1c) was 7.5 (1.4) and 8.5 (1.6) in Types 2 and 1 DM patients, respectively, whereas a slightly higher proportion of patients had >11.0 HbA1c in Type 1 DM (5.8%) than Type 2 (2.0%). The mean (SD) duration of Type 2 DM was shorter compared with Type 1 (7.5 [5.2] vs 10.3 [6.9] years). In Type 2 DM patients, there were 516 (15.5%) cases of DR, 19 (0.56%) of proliferative DR (PDR), and 106 (3.11%) of diabetic macular edema (DME). In Type 1 DM patients, there were 86 (29.15%) cases of DR, 10 (3.39%) PDR, and 12 (4.07%) DME.

Conclusions

In Slovakian patients with DM, the duration of disease and higher HbA1c were the most prevalent factors that contributed to the development of DR and DME.

Klíčová slova:

Diabetic retinopathy – Epidemiology – Type 1 diabetes – Slovakian people – Slovakia


Zdroje

1. IDF DIABETES ATLAS—8TH EDITION. http://www.diabetesatlas.org/across-the-globe.html (accessed on 28 November 2017).

2. Johnston AW. Near visual acuity tests using Chinese characters and the logMAR principle. Singapore Med J. 1985;26(6):448–55. 4095558.

3. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018;138:271–81. Epub 2018/03/03. doi: 10.1016/j.diabres.2018.02.023 29496507.

4. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–51. Epub 2005/01/11. 15640920.

5. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes care. 2012;35(3):556–64. Epub 2012/02/04. doi: 10.2337/dc11-1909 22301125.

6. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36. Epub 2010/06/29. doi: 10.1016/S0140-6736(09)62124-3 20580421.

7. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. Jama. 2007;298(8):902–16. Epub 2007/08/23. doi: 10.1001/jama.298.8.902 17712074.

8. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83. Epub 2007/09/27. doi: 10.1080/09286580701396720 17896294.

9. Cho NH, Kim TH, Woo SJ, Park KH, Lim S, Cho YM, et al. Optimal HbA1c cutoff for detecting diabetic retinopathy. Acta Diabetol. 2013;50(6):837–42. Epub 2013/01/29. doi: 10.1007/s00592-013-0452-3 23354926.

10. Park S, Rhee SY, Jeong SJ, Kim K, Chon S, Yu SY, et al. Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data. Diabetes Metab J. 2017;41(5):393–404. Epub 2017/11/01. doi: 10.4093/dmj.2017.41.5.393 29086538.

11. Chisha Y, Terefe W, Assefa H, Lakew S. Prevalence and factors associated with diabetic retinopathy among diabetic patients at Arbaminch General Hospital, Ethiopia: Cross sectional study. PLoS One. 2017;12(3):e0171987. Epub 2017/03/03. doi: 10.1371/journal.pone.0171987 28253261.

12. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2012;35(6):1364–79. Epub 2012/04/21. doi: 10.2337/dc12-0413 22517736.

13. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047–53. Epub 2004/04/28. doi: 10.2337/diacare.27.5.1047 15111519.

14. Larsen MB, Henriksen JE, Grauslund J, Peto T. Prevalence and risk factors for diabetic retinopathy in 17 152 patients from the island of Funen, Denmark. Acta ophthalmologica. 2017;95(8):778–86. Epub 2017/04/27. doi: 10.1111/aos.13449 28444837.

15. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010;53(10):2147–54. Epub 2010/07/03. doi: 10.1007/s00125-010-1836-3 20596693.

16. Younis N, Broadbent DM, Harding SP, Vora JR. Prevalence of diabetic eye disease in patients entering a systematic primary care-based eye screening programme. Diabet Med. 2002;19(12):1014–21. Epub 2003/03/22. doi: 10.1046/j.1464-5491.2002.00854.x 12647843.

17. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. The British journal of ophthalmology. 2015;99(1):64–8. Epub 2014/08/06. doi: 10.1136/bjophthalmol-2013-304017 25091950.

18. Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. The British journal of ophthalmology. 2017;101(10):1346–51. Epub 2017/03/09. doi: 10.1136/bjophthalmol-2016-310063 28270484.

19. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The North Jutland County Diabetic Retinopathy Study: population characteristics. The British journal of ophthalmology. 2006;90(11):1404–9. Epub 2006/07/11. doi: 10.1136/bjo.2006.093393 16825278.

20. Kaidonis G, Mills RA, Landers J, Lake SR, Burdon KP, Craig JE. Review of the prevalence of diabetic retinopathy in Indigenous Australians. Clinical & experimental ophthalmology. 2014;42(9):875–82. Epub 2014/03/29. doi: 10.1111/ceo.12338 24666566.

21. Petrella RJ, Blouin J, Davies B, Barbeau M. Prevalence, Demographics, and Treatment Characteristics of Visual Impairment due to Diabetic Macular Edema in a Representative Canadian Cohort. Journal of ophthalmology. 2012;2012:159167. Epub 2013/01/11. doi: 10.1155/2012/159167 23304447.

22. Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu MD, Toft I, et al. Tromso eye study: prevalence and risk factors of diabetic retinopathy. Acta ophthalmologica. 2013;91(8):716–21. Epub 2012/09/22. doi: 10.1111/j.1755-3768.2012.02542.x 22994366.

23. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800–11. Epub 2010/03/05. doi: 10.1056/NEJMoa0908359 20200384.

24. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. Jama. 1988;260(1):37–41. Epub 1988/07/01. 2898025.

25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53. Epub 1998/09/22. 9742976.

26. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed). 1986;293(6556):1195–9. Epub 1986/11/08. doi: 10.1136/bmj.293.6556.1195 3096429.

27. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811–5. Epub 1985/03/16. doi: 10.1136/bmj.290.6471.811 3919804.

28. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. Epub 1993/09/30. doi: 10.1056/NEJM199309303291401 8366922.

29. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304–9. Epub 1993/07/29. doi: 10.1056/NEJM199307293290502 8147960.

30. Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England journal of medicine. 2008;358(24):2545–59. Epub 2008/06/10. doi: 10.1056/NEJMoa0802743 18539917.

31. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine. 2008;358(24):2560–72. Epub 2008/06/10. doi: 10.1056/NEJMoa0802987 18539916.

32. Zhou Y, Zhang Y, Shi K, Wang C. Body mass index and risk of diabetic retinopathy: A meta-analysis and systematic review. Medicine (Baltimore). 2017;96(22):e6754. Epub 2017/06/01. doi: 10.1097/md.0000000000006754 28562529.


Článek vyšel v časopise

PLOS One


2019 Číslo 12